## **Brian Johnston**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1123907/publications.pdf

Version: 2024-02-01

361296 276775 2,197 46 20 41 citations h-index g-index papers 47 47 47 2218 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA. American Journal of Infection Control, 2023, 51, 434-439.	1.1	1
2	Intestinal Persistence of Colonizing <i>Escherichia coli</i> Strains, Especially ST131- <i>H</i> 30, in Relation to Bacterial and Host Factors. Journal of Infectious Diseases, 2022, 225, 2197-2207.	1.9	9
3	Draft Genome Sequences of Sixteen Fluoroquinolone-Resistant Extraintestinal Escherichia coli Isolates from Human Patients. Microbiology Resource Announcements, 2022, , e0000322.	0.3	O
4	Bacteriophage Cocktail and Microcin-Producing Probiotic Escherichia coli Protect Mice Against Gut Colonization With Multidrug-Resistant Escherichia coli Sequence Type 131. Frontiers in Microbiology, 2022, 13, 887799.	1.5	14
5	Complete Genome Sequence of Escherichia coli Strain FEX669, a ColV Plasmid-Containing Isolate from Retail Chicken Meat. Microbiology Resource Announcements, 2021, 10, .	0.3	1
6	Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012–2017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and resistance to comparator agents. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2069-2075.	1.3	2
7	Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012–20017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and coresistance. Diagnostic Microbiology and Infectious Disease. 2021. 100. 115314.	0.8	4
8	Activity of plazomicin against carbapenem-intermediate or -resistant <i>Escherichia coli</i> isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. Journal of Antimicrobial Chemotherapy, 2021, 76, 2061-2070.	1.3	5
9	Global molecular epidemiology of carbapenem-resistant Escherichia coli (2002–2017). European Journal of Clinical Microbiology and Infectious Diseases, 2021, , 1.	1.3	14
10	Core Genome Multi-Locus Sequence Typing and Prediction of Antimicrobial Susceptibility Using Whole Genome Sequences of Escherichia coli Bloodstream Infection Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0113921.	1.4	2
11	Molecular Characteristics, Ecology, and Zoonotic Potential of Escherichia coli Strains That Cause Hemorrhagic Pneumonia in Animals. Applied and Environmental Microbiology, 2021, 87, e0147121.	1.4	1
12	<i>In Silico</i> Genotyping of Escherichia coli Isolates for Extraintestinal Virulence Genes by Use of Whole-Genome Sequencing Data. Journal of Clinical Microbiology, 2020, 58, .	1.8	179
13	Draft genome sequences of concurrent Escherichia coli blood and fecal isolates from a patient with bacteremia and diarrhea belie BioFire-based detection of fecal enteropathogenic E. coli. Pathogens and Disease, 2020, 78, .	0.8	1
14	Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	24
15	Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115034.	0.8	2
16	Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	13
17	Molecularly defined extraintestinal pathogenic <i>Escherichia coli</i> status predicts virulence in a murine sepsis model better than does virotype, individual virulence genes, or clonal subset among <i>E. coli</i> ST131 isolates. Virulence, 2020, 11, 327-336.	1.8	15
18	Accessory Traits and Phylogenetic Background Predict Escherichia coli Extraintestinal Virulence Better Than Does Ecological Source. Journal of Infectious Diseases, 2019, 219, 121-132.	1.9	38

#	Article	IF	Citations
19	Survey of US wastewater for carbapenem-resistant <i>Enterobacteriaceae</i> . Journal of Water and Health, 2019, 17, 219-226.	1.1	32
20	Rapid Emergence, Subsidence, and Molecular Detection of <i>Escherichia coli</i> Sequence Type 1193- fimH64 , a New Disseminated Multidrug-Resistant Commensal and Extraintestinal Pathogen. Journal of Clinical Microbiology, 2019, 57, .	1.8	56
21	1438. Escherichia coli (EC) ST131-H30 Clonal Group is Associated with Antimicrobial Resistance, Illness Severity, Host Compromise, and Non-Cure among Patients with Bacteriuria. Open Forum Infectious Diseases, 2019, 6, S525-S525.	0.4	0
22	Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status. PLoS ONE, 2018, 13, e0200442.	1.1	2
23	Rapid and Specific Detection of the Escherichia coli Sequence Type 648 Complex within Phylogroup F. Journal of Clinical Microbiology, 2017, 55, 1116-1121.	1.8	35
24	Clonal distribution and associated characteristics of Escherichia coli clinical and surveillance isolates from a military medical center. Diagnostic Microbiology and Infectious Disease, 2017, 87, 382-385.	0.8	20
25	Fine-Scale Structure Analysis Shows Epidemic Patterns of Clonal Complex 95, a Cosmopolitan Escherichia coli Lineage Responsible for Extraintestinal Infection. MSphere, 2017, 2, .	1.3	32
26	Epidemiology and characteristics of Escherichia coli sequence type 131 (ST131) from long-term care facility residents colonized intestinally with fluoroquinolone-resistant Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2017, 87, 275-280.	0.8	8
27	Phylogenetic Backgrounds and Virulence-Associated Traits of Escherichia coli Isolates from Surface Waters and Diverse Animals in Minnesota and Wisconsin. Applied and Environmental Microbiology, 2017, 83, .	1.4	13
28	Virulence genes and subclone status as markers of experimental virulence in a murine sepsis model among Escherichia coli sequence type 131 clinical isolates from Spain. PLoS ONE, 2017, 12, e0188838.	1.1	7
29	Household Clustering of Escherichia coli Sequence Type 131 Clinical and Fecal Isolates According to Whole Genome Sequence Analysis. Open Forum Infectious Diseases, 2016, 3, ofw129.	0.4	62
30	Escherichia coli Sequence Type $131 < i > H < /i > 30$ Is the Main Driver of Emerging Extended-Spectrum- $\hat{l}^2$ -Lactamase-Producing E. coli at a Tertiary Care Center. MSphere, 2016, 1, .	1.3	9
31	Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection. Applied and Environmental Microbiology, 2016, 82, 2686-2692.	1.4	33
32	Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype. Antimicrobial Agents and Chemotherapy, 2016, 60, 1888-1891.	1.4	10
33	Evaluation of CTX-M steady-state mRNA, mRNA half-life and protein production in various STs of <i>Escherichia coli </i> i> Journal of Antimicrobial Chemotherapy, 2016, 71, 607-616.	1.3	11
34	Gut Colonization of Healthy Children and Their Mothers With Pathogenic Ciprofloxacin-Resistant <i>Escherichia coli</i> Journal of Infectious Diseases, 2015, 212, 1862-1868.	1.9	60
35	Clinical and Microbiological Determinants of Infection After Transrectal Prostate Biopsy. Clinical Infectious Diseases, 2015, 60, 979-987.	2.9	49
36	Intensity and Mechanisms of Fluoroquinolone Resistance within the <i>H</i> 30 and <i>H</i> 30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli. Antimicrobial Agents and Chemotherapy, 2015, 59, 4471-4480.	1.4	68

#	Article	IF	CITATIONS
37	Colonization with Escherichia coli Strains among Female Sex Partners of Men with Febrile Urinary Tract Infection. Journal of Clinical Microbiology, 2015, 53, 1947-1950.	1.8	16
38	Host Characteristics and Bacterial Traits Predict Experimental Virulence for Escherichia coli Bloodstream Isolates From Patients With Urosepsis. Open Forum Infectious Diseases, 2015, 2, ofv083.	0.4	100
39	Clinical and Molecular Epidemiology of Escherichia coli Sequence Type 131 among Hospitalized Patients Colonized Intestinally with Fluoroquinolone-Resistant E. coli. Antimicrobial Agents and Chemotherapy, 2014, 58, 7003-7006.	1.4	8
40	Temporal Trends in Antimicrobial Resistance and Virulence-Associated Traits within the Escherichia coli Sequence Type 131 Clonal Group and Its $\langle i\rangle H\langle  i\rangle$ 30 and $\langle i\rangle H\langle  i\rangle$ 30-Rx Subclones, 1968 to 2012. Antimicrobial Agents and Chemotherapy, 2014, 58, 6886-6895.	1.4	45
41	Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli. Journal of Infectious Diseases, 2013, 207, 919-928.	1.9	247
42	Escherichia coli Sequence Type 131 (ST131) Subclone H30 as an Emergent Multidrug-Resistant Pathogen Among US Veterans. Clinical Infectious Diseases, 2013, 57, 1256-1265.	2.9	167
43	The Epidemic of Extended-Spectrum- $\hat{l}^2$ -Lactamase-Producing Escherichia coli ST131 Is Driven by a Single Highly Pathogenic Subclone, <i>H</i>	1.8	380
44	Four Main Virotypes among Extended-Spectrum- $\hat{l}^2$ -Lactamase-Producing Isolates of Escherichia coli O25b:H4-B2-ST131: Bacterial, Epidemiological, and Clinical Characteristics. Journal of Clinical Microbiology, 2013, 51, 3358-3367.	1.8	76
45	Enteroaggregative Escherichia coli O78:H10, the Cause of an Outbreak of Urinary Tract Infection. Journal of Clinical Microbiology, 2012, 50, 3703-3711.	1.8	77
46	Epidemic Clonal Groups of <i>Escherichia coli</i> as a Cause of Antimicrobial-Resistant Urinary Tract Infections in Canada, 2002 to 2004. Antimicrobial Agents and Chemotherapy, 2009, 53, 2733-2739.	1.4	249